Docetaxel in paclitaxel-pretreated advanced breast cancer patients
Cecilia Nisticò(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), E. Terzoli(Catholic University of America), N. Rosati, Michele Stanislaw Milella(University of Verona), Angela Vaccaro(Accademia di Belle Arti di Frosinone), Carlo Garufi(Fondazione IRCCS Istituto Nazionale dei Tumori), Paola Papaldo(Cancer Institute (WIA)), Francesco Tropea, A.M. D'Ottavio(Cancer Institute (WIA)), A. Zappalà
Cited by 0
Related Papers
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
|The Lancet Oncology|2018|579
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
|Modern Pathology|2015|317
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial
|The Lancet|2015|202
Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. Italian Multicentre Breast Study with Epirubicin.
|Journal of Clinical Oncology|1988|168
Lonidamine: Efficacy and safety in clinical trials for thetreatment of solid tumors
|Drugs of today|2003|168